INFORMATION AND SERVICES EXCLUSIVELY FOR US HEALTHCARE PROFESSIONALS

WARNING: ASTHMA-RELATED DEATH

  • Long-acting beta2-adrenergic agonists (LABAs), such as vilanterol, one of the active ingredients in BREO ELLIPTA, increase the risk of asthma-related death.

...continue reading

Indications

  • BREO ELLIPTA is a combination inhaled corticosteroid/long-acting beta2-adrenergic agonist (ICS/LABA) indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. BREO ELLIPTA is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.
  • BREO ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma.

227436R0 March 2015